Eplerenone for Central Serous: What the VICI Trial Actually Showed
The Short Version of the VICI Trial Result
If you have central serous chorioretinopathy (CSC) and have been offered a pill called eplerenone, you deserve a plain answer about whether it works. A large, carefully run trial gave one. In the VICI trial, a randomized, double-blind, placebo-controlled study of 114 patients, eplerenone was no better than a dummy pill at improving vision in chronic CSC after 12 months, and the authors recommended discouraging its use1. In short, the best evidence does not support eplerenone for this condition.
This is disappointing if you hoped for a simple tablet, but it is genuinely useful to know. It spares you a medicine that the strongest study found did not help, along with its cost and side effects. Most cases of central serous chorioretinopathy settle within about 3 months on their own without any treatment2. For many people, watchful waiting with an eye specialist is a reasonable first step rather than rushing to a drug.
A negative result for one drug is not the end of the road. The VICI trial tested eplerenone specifically; it did not test the other approaches that specialists still use for stubborn cases. It also did not mean CSC is untreatable. The takeaway is narrow and honest: this particular pill did not beat placebo, so attention has turned to better-supported options and to new research.
Central Serous and Eplerenone: The Background
Central serous chorioretinopathy happens when fluid builds up under the retina, lifting it slightly and blurring or distorting your central vision2. You might notice a dim or dark patch in the middle of your sight, straight lines that look bent, or objects that seem smaller or farther away. Because it usually affects one eye and often clears up, it can be frightening at first but is frequently not permanent.
CSC most often affects people between about 35 and 55 years old and is more common in men, with links to corticosteroid use and periods of emotional stress2. Any form of steroid medication can bring on or worsen CSC, so specialists often look for steroids to stop where it is safe to do so3. If you take a steroid inhaler, cream, or tablet, mention it to your eye doctor.
Eplerenone is a blood-pressure medicine that blocks a hormone receptor thought to play a role in CSC. Early, small studies looked promising, and many ophthalmologists began prescribing eplerenone off-label as a first-line treatment for CSC before large trial evidence was available1. That hopeful but thin evidence base is exactly why a proper randomized trial was needed to settle the question.
What the VICI Trial Actually Found
The VICI trial was built to give a trustworthy answer. It randomly assigned 114 patients with chronic CSC, in a one-to-one split, to take either oral eplerenone or a matching placebo, with neither patients nor assessors knowing which they received1. This double-blind, placebo-controlled design is the standard for telling a real drug effect apart from natural recovery or wishful thinking.
The primary question was whether eplerenone improved vision. At 12 months, there was no meaningful difference in best-corrected visual acuity between the eplerenone and placebo groups1. In other words, people taking the drug did not see better, on average, than people taking a sugar pill. For a treatment given daily for a year, that is a clear signal of limited benefit.
Doctors also looked at the fluid under the retina, an anatomical measure. The secondary anatomical outcomes did not favor eplerenone either, and one measure of retinal fluid at 12 months slightly favored the placebo group1. So the drug did not clearly dry up the fluid any better than doing nothing. Both the vision and the anatomy pointed the same, unfavorable way.
The trial team was direct about the implication. Based on these results, the authors recommended that ophthalmologists discourage the use of eplerenone for CSC and instead encourage patients to join clinical trials of other therapies1. That is a strong statement, and it reflects how much weight a well-designed randomized trial carries compared with earlier small reports.
How Much Weight Should You Give This Result?
Not all evidence is equal, and this sits near the top. Because VICI randomly assigned patients and kept both patients and assessors unaware of the treatment, its finding of no benefit carries more weight than the earlier small, non-randomized studies that had suggested eplerenone might help. Randomization is what stops the natural tendency of CSC to improve on its own from being mistaken for a drug effect.
Even a strong trial has boundaries. VICI studied one drug, at the doses used, in people with chronic disease lasting more than four months, so it does not speak to brand-new cases or to other treatments. It cannot rule out a tiny benefit in some subgroup. But for the practical question most patients ask, does this pill meaningfully help chronic CSC, the answer it gives is no.
Science works by testing hopeful ideas rigorously, and sometimes they do not pan out. The earlier enthusiasm for eplerenone came from small studies that could not separate the drug from the condition's own habit of resolving. VICI applied a stricter test and the apparent benefit disappeared. That pattern, promising small studies overturned by a large randomized trial, is common in medicine and a reason to value trials like this one.
What This Means for Treating Central Serous Now
Losing eplerenone as an option does not leave you empty-handed. For cases that do not resolve on their own, retina specialists may use photodynamic therapy, a low-energy laser, or other laser treatment, and they first look to reduce any steroid medication that could be driving the fluid3. When treatment is needed, doctors aim to seal the leak and help vision recover, though they usually watch first to see whether the fluid clears by itself2. Your specialist tailors the choice to your case.
The overall picture is more reassuring than a negative drug trial might suggest. Most people with CSC regain good vision even without treatment, although vision does not always return fully and the condition can come back2. Chronic or repeated episodes carry more risk to sight, which is why staying under the care of a retina specialist matters even when the news about one drug is disappointing.
If you are already taking eplerenone for CSC, do not simply stop on your own; talk with the doctor who prescribed it. The VICI result is a reason to revisit the plan together, not to make an abrupt change alone. Ask what the goal of the medicine is for you, whether the evidence supports continuing, and what the better-studied alternatives would be for your situation.
When to See an Eye Doctor About Central Serous
Some vision changes should not wait. Call an eye doctor the same day if you notice any of the following:
- A sudden, significant drop in your central vision.
- A new dark spot or blind patch in the middle of your sight.
- Straight lines that suddenly look badly bent or broken.
- A curtain, shadow, or shower of new floaters and flashes, which can signal a different, urgent problem.
If you notice any of these, do not wait for a routine appointment. A sudden change needs a same-day look to rule out something more serious and to start the right care quickly. Many CSC changes do come on gradually, but a sudden shift is the one to act on right away.
CSC is usually followed over time rather than treated right away. Your eye doctor will check your vision and image the back of the eye to see whether the fluid is clearing, and many people track their own vision at home with an Amsler grid between visits. Keeping these appointments is how a chronic case that needs treatment gets caught before it harms your sight.
CSC that lingers or comes back needs specialist attention. Chronic central serous chorioretinopathy may be treated with photodynamic therapy or laser once any contributing steroid medication is reduced3. Those imaging-guided treatments are handled by a retina specialist, and your optometrist or general ophthalmologist can make that referral, so you do not have to find the right specialist on your own.
Frequently Asked Questions About Eplerenone and Central Serous
Not exactly, but it sets the expectation low. Across 114 patients, eplerenone did not improve vision more than placebo at 12 months, which is why the trial's authors discouraged its routine use1. A rare individual response cannot be completely ruled out, but the strongest evidence says most people should not expect a benefit. That is worth weighing against the drug's cost and possible side effects with your doctor.
Do not stop on your own; talk with your prescriber first. Eplerenone affects blood pressure and potassium, so changes should be made with medical guidance rather than abruptly. The VICI result is a good reason to review the plan together and ask whether continuing makes sense for you. Your doctor can suggest a safe way forward and discuss better-studied options for your CSC.
Several options exist for cases that do not clear on their own. Retina specialists may use photodynamic therapy or laser treatment for chronic CSC and will first try to reduce any steroid medication that could be contributing3. The right choice depends on where the fluid is leaking and how long it has been present. A retina specialist can explain which approach fits your eye.
Often, yes. Most cases of CSC resolve within about 3 months without treatment, and most people regain good vision even without a procedure2. That natural recovery is one reason a daily pill is hard to justify unless it clearly beats doing nothing, which eplerenone did not. Your doctor will usually watch first and step in only if the fluid persists.
More Questions About Central Serous Chorioretinopathy
They are among the best-known links. CSC has been associated with emotional stress and with corticosteroid use in any form, including inhalers, creams, and tablets3. That does not mean stress alone is to blame, but reducing avoidable steroids and managing stress are sensible steps. Always tell your eye doctor about every steroid medicine you use, since some are easy to overlook.
It was a reasonable idea that early evidence seemed to support. Small studies had suggested eplerenone might help, so many ophthalmologists used it off-label as a first-line treatment before a large randomized trial tested it properly1. When VICI applied a stricter test, the benefit did not hold up. This is a normal and healthy part of how medicine corrects itself as better evidence arrives.
No, and it is important not to read it that way. The trial was about one drug, not about your chances of recovering. Most people with CSC regain good vision, often without any treatment, and effective procedures exist for cases that do not settle on their own2. Staying in the care of a retina specialist gives you the best chance of protecting your vision over time.
- Is my central serous acute or chronic, and how long has the fluid been present?
- Given the VICI results, do you recommend against eplerenone for me?
- Am I taking any steroid medicine that could be making this worse?
- Would watchful waiting, photodynamic therapy, or laser be best for my case?
- When should I be referred to a retina specialist, and how will we monitor my vision?
- American Academy of Ophthalmology (EyeNet) (2020). Eplerenone or Placebo for Chronic Central Serous Chorioretinopathy.
- American Academy of Ophthalmology (EyeSmart) (2023). What Is Central Serous Chorioretinopathy?.
- American Society of Retina Specialists (2022). Central Serous Chorioretinopathy (Patients).